$KIN [positive]Kindred Biosciences (KIN) Reports Next Week: Wall Street Expects Earnings Growth
11:33 am ET July 29, 2020 (Zacks) Print
The market expects Kindred Biosciences (KIN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on August 5, 2020, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This biopharmaceutical company is expected to post quarterly earnings of $0.15 per share in its upcoming report, which represents a year-over-year change of +140.5%.
Revenues are expected to be $19.82 million, up 1498.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
